Feasibility of a Multimodal Intervention Program to Optimize Treatment Outcomes in Ulcerative Colitis (OPTIMIZE-UC)

September 17, 2026 updated by: Radboud University Medical Center

OPTIMIZE-UC: Feasibility of a Multimodal Intervention Program to Optimize Treatment Outcomes in Ulcerative Colitis: A Prospective Pilot Study

This is a prospective, interventional pilot study to assess the feasibility and optimal timing of a multimodal intervention program in Ulcerative Colitis (UC) patients with active disease as well as in patients in remission. Secondly, to demonstrate the effects of a multimodal intervention program on individual patients level and therapy outcomes.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Rationale: Despite considerable advances in the knowledge of UC, and a variation of treatment options, UC still impacts patients' ability to lead a normal life. Clearly, there is an unmet need to improve treatment outcomes. Prehabilitation programs in surgery have shown that the amount of complications is closely related to preoperative physical fitness, nutritional status and psychological well-being. IBD patients often search for self-management strategies to manage their symptoms, however, research focussing on a multimodal intervention approach in parallel to starting new IBD treatment is lacking. Given the potential benefits of intervention programs, limitations of current treatments in terms of improving quality of life and patients' desire for self-management options, we believe that exploring the results of a multimodal intervention program in patients with UC is of high relevance.

Objective/study design: This is a prospective, interventional pilot study to assess the feasibility and optimal timing of a multimodal intervention program in UC patients. Secondly, to demonstrate the effects of a multimodal intervention program on individual patients level and therapy outcomes.

Study population: Patients ≥ 18 years old, with UC. Intervention: Multimodal intervention program including an exercise program, nutritional intervention and psychological evaluation.

Main study parameters/endpoints: This study assesses the feasibility of a multimodal intervention program. Secondary, assesses the effect on:

  • Individual patients' level, i.e. physical fitness, nutritional status, mental health, quality of life and work productivity and activity impairment.
  • Therapy outcomes, e.g. adherence, number and severity of (S)AEs, corticosteroid use, biochemical and clinical response/remission rates and patient reported outcomes.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Nijmegen, Netherlands, 6525GA
        • Dorien Oomkens

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥ 18 years old;
  • Diagnosis of UC confirmed by clinical, endoscopic, and/or histological evidence prior to screening as per standard criteria;
  • Ability of subject to participate fully in all aspects of this project;
  • Written informed consent must be obtained and documented.

Exclusion Criteria:

  • Suspicion of differential diagnosis of CD, indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis;
  • Serious underlying disease other than UC that in the opinion of the investigator may interfere with the subject's ability to participate fully in the study or would compromise subject safety (such as history of malignancies, major neurological disorders, certain orthopedic impairments or any unstable, uncontrolled or severe systemic medical disorder);
  • History of alcohol or drug abuse that in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures;
  • History of psychiatric disorders that in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures;
  • If female, the subject is pregnant or lactating (< 1 year) or intending to become pregnant;
  • Immobilized patients who are not able to complete exercise intervention;
  • Illiteracy (disability to read and understand Dutch).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patients with ulcerative colitis

Patients participate in multimodal intervention

Exercise intervention: combined endurance and resistance training three times a week using workout video's which patients can do at home. Advice to exercise at low-intensity for at least 30 minutes per day.

Nutritional intervention: Patients are advised to aim for optimal energy and protein intake (by registered dietician) and to avoid red meat, processed foods and sweetened drinks. Aiming for a mainly plant based diet.

Psychological intervention: screening for psychological risk factors and if present, patients are referred to a psychologist for psychological support.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Accrural
Time Frame: 24 weeks

The percentage of approached, eligible participants that are included in the study.

24 weeks
Attrition
Time Frame: 24 weeks

The percentage of participants who stopped the program prematurely.

24 weeks
Adherence to exercise program
Time Frame: 24 weeks

Frequency of followed trainings

24 weeks
Adherence to daily exercise goals
Time Frame: 24 weeks

SQUASH questionnaire

24 weeks
Patient satisfaction
Time Frame: 24 weeks

Measured using a patient satisfaction questionnaire

24 weeks
Safety and adverse events
Time Frame: 24 weeks

Measured by the number of adverse events occurring during the program

24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Oxygen Consumption (VO2 max)
Time Frame: 1 year

Indication of physical fitness

1 year
Change in 1 repitition measures
Time Frame: 1 year

Indication of muscle strength

1 year
Change in body weight
Time Frame: 1 year

Measured in kilograms

1 year
Change in fat-free mass
Time Frame: 1 year

Measured with bioelectrical impedance analysis (BIA)

1 year
Change in nutritional status
Time Frame: 1 year

Measured with Patient Generated Subjective Global Assessment (PG-SGA)

1 year
Change in mental health
Time Frame: 1 year

Hospital Anxiety and Depression scale (HADS questionnaire)

1 year
Change in Work Productivity and Activity Impairment
Time Frame: 1 year

Work Productivity and Activity Impairment Questionnaire (including WPAI-GH)

1 year
Change in 36-Item Short Form Health Survey (SF-36) score
Time Frame: 1 year

Quality of life

1 year
Change in EuroQoL (EQ-5D-5L) score
Time Frame: 1 year

Quality of life

1 year
Change in Inflammatory Bowel Disease Questionnaire score
Time Frame: 1 year

Disease-related quality of life

1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2024

Primary Completion (Actual)

March 1, 2025

Study Completion (Actual)

March 1, 2026

Study Registration Dates

First Submitted

January 20, 2023

First Submitted That Met QC Criteria

February 14, 2023

First Posted (Actual)

February 24, 2023

Study Record Updates

Last Update Posted (Actual)

September 22, 2026

Last Update Submitted That Met QC Criteria

September 17, 2026

Last Verified

January 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 114110

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.